[go: up one dir, main page]

WO2018056616A1 - Procédé de recherche par criblage d'un agent thérapeutique à base de cellules souches spécifiques d'un patient - Google Patents

Procédé de recherche par criblage d'un agent thérapeutique à base de cellules souches spécifiques d'un patient Download PDF

Info

Publication number
WO2018056616A1
WO2018056616A1 PCT/KR2017/009839 KR2017009839W WO2018056616A1 WO 2018056616 A1 WO2018056616 A1 WO 2018056616A1 KR 2017009839 W KR2017009839 W KR 2017009839W WO 2018056616 A1 WO2018056616 A1 WO 2018056616A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
cells
stem cells
derived
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/009839
Other languages
English (en)
Korean (ko)
Inventor
장종욱
나덕렬
이정민
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Life Public Welfare Foundation
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of WO2018056616A1 publication Critical patent/WO2018056616A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to a method for screening a patient-specific stem cell therapy.
  • Suitable therapeutic agents may be different.
  • the disease-causing variation may vary from patient to patient, so selecting a therapeutic agent suitable for a patient-specific mutation is a very important problem, and securing a method for screening a patient-specific treatment agent. Is needed.
  • the inventors of the present invention are studying a method for selecting a patient-specific customized therapeutic agent, co-culturing a patient-derived cell and a candidate group of mesenchymal stem cells, and confirming the change of the patient-derived cell according to the co-culture.
  • the present invention was completed by confirming that stem cells showing a particularly excellent effect on patients or diseases can be selected quickly.
  • an object of the present invention is to provide a method for screening a patient-specific stem cell therapy.
  • the present invention comprises the steps of (1) co-culturing the patient-derived cells and candidate stem cells; And (2) selecting stem cells by measuring changes in proliferative, differentiating or pathological markers of patient derived cells; It provides a method for screening a patient-specific stem cell therapy comprising a.
  • FIG. 1 is a schematic diagram showing a co-culture method of a screening model for selecting stem cells showing an excellent therapeutic effect on Alzheimer's dementia (AD) neuron cells.
  • AD Alzheimer's dementia
  • Figure 2 is a cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (WJ-MSC) or fat-derived mesenchymal stem cells (Adipose-MSC) in the treatment group to check the degree of cell activity to prevent cell death The figure which showed the result which confirmed the effect.
  • UB-MSC cord blood-derived mesenchymal stem cells
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC fat-derived mesenchymal stem cells
  • FIG. 3 is a diagram showing the results of the classification of secretion proteins by function of umbilical cord-derived mesenchymal stem cells (WJ-MSC) treatment group.
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Figure 4 is a diagram showing the results of the classification of secreted proteins by the function of adipose-derived mesenchymal stem cells (Adipose-MSC) treatment group.
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • FIG. 5 is a diagram showing a method for establishing a stem cell therapeutic screening model for each Alzheimer's type dementia subtype.
  • Figure 6 shows the expression level of SOX2 and Nestin of APP-NPC or PS-1-NPC in adipose-derived mesenchymal stem cells (Adipose-MSC) treatment group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treatment group Is a diagram showing.
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • WJ-MSC umbilical cord-derived mesenchymal stem cell
  • MAP2 and Tuj1 Neuron-specific class III of APP-NPC or PS-1-NPC in adipose-derived mesenchymal stem cell (Adipose-MSC) treated group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treated group.
  • Adipose-MSC adipose-derived mesenchymal stem cell
  • WJ-MSC umbilical cord-derived mesenchymal stem cell
  • Figure 8 shows the co-culture of Alzheimer subtype-derived PS1-NPC, sAD (Sporadic AD) -NPC and fat-derived mesenchymal stem cells (Adipose-MSC) treatment group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treatment group It is a figure which shows the result of comparing cell proliferation ability.
  • Figure 9 compares the cell proliferation capacity of co-culture of Alzheimer subtype-derived PS1-NPC, sAD-NPC and adipose-derived mesenchymal stem cell (Adipose-MSC) treatment group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treatment group
  • Figure 1 shows the results.
  • FIG. 10 shows the pathological factor ubiquitin according to co-culture of Alzheimer subtype-derived PS1-NPC, sAD-NPC and adipose-derived mesenchymal stem cell (Adipose-MSC) treated group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treated group. It is a figure which shows the result of comparing and quantifying the change of expression of a conjugate.
  • FIG. 11 is a diagram showing a method for establishing a stem cell therapeutic screening model using neurons derived from Alzheimer's disease patients.
  • Figure 12 compares and quantified the expression changes of ubiquitin conjugates according to co-culture of Alzheimer's patients-derived neurons and adipose-derived mesenchymal stem cells (Adipose-MSC) treatment group or umbilical cord-derived mesenchymal stem cell (WJ-MSC) treatment group. The results are shown.
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • WJ-MSC umbilical cord-derived mesenchymal stem cell
  • the present invention comprises the steps of (1) co-culturing the patient-derived cells and candidate stem cells; And (2) selecting stem cells by measuring changes in proliferative, differentiating or pathological markers of patient derived cells; It provides a method for screening a patient-specific stem cell therapy comprising a.
  • the screening method of the present invention enables the rapid selection of stem cells that can have the most effect on patient cells, and thus can be effectively used for screening patient-specific stem cell therapeutics and developing them as therapeutic agents.
  • the present invention will be described in detail.
  • Step (1) of the present invention is a step of co-culturing patient derived cells and candidate stem cells.
  • patient-derived cell means a cell isolated and obtained from a patient, and since the cell is directly isolated from the patient, a cell having a characteristic capable of reflecting all genetic and pathological factors of the individual patient. it means. Therefore, it can be expected that the selected stem cell therapeutics that have an effect on the patient-derived cells will have an excellent effect on the patient.
  • the patient-derived cell may be a cell derived from a patient having each disease subtype, and when used, it is possible to effectively select a stem cell therapeutic agent having a particular effect on a specific disease subtype.
  • the patient-derived cells of the present invention may preferably be cells derived from a patient with degenerative brain disease, and the cells derived from the patient with degenerative brain disease are derived differentiated stem cells derived from patients with degenerative brain disease or subtypes thereof (Induced Pluripotent Stem Cell, iPSC), nerve cell or nerve progenitor cell nerve.
  • iPSC Insulated Pluripotent Stem Cell
  • the "degenerative brain disease” is a specific brain cell group of the brain and spinal cord gradually loses its function, the death of cerebral neurons which is most important for information transmission of the nervous system, synapses that transmit information between the brain neurons and brain nerve cells It is a disease caused by the formation or function problems of the brain and the ideal increase or decrease of electrical activity of the cranial nerve.
  • Degenerative brain diseases are classified by considering the main symptoms and invading brain areas, and include Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD).
  • the degenerative brain disease of the present invention may be one or more selected from the group consisting of forgetfulness, dementia, Alzheimer's disease, Parkinson's disease and Huntington's disease.
  • the "candidate stem cell” means a stem cell population used for the purpose of selecting stem cells showing the best effect.
  • the candidate stem cells cells showing the best effect on the patient-derived cells as compared to other stem cells can be selected as a patient-specific stem cell therapy.
  • Candidate stem cells of step (1) may be derived from one or more selected from the group consisting of cord blood, umbilical cord, bone marrow and fat.
  • the stem cells may be mesenchymal stem cells. According to the screening method of the present invention, it is possible to select a stem cell showing the most excellent effect on the patient-specific, subtype-specific.
  • the effect of each candidate stem cells on Alzheimer's patients derived neuro precursor cells, neurons, and improve the pathological state of Alzheimer's To this end, umbilical cord-derived mesenchymal stem cells are appropriate, and for the purpose of proliferation of neurons, it was confirmed that it is preferable to select umbilical cord-derived mesenchymal stem cells rather than fat-derived mesenchymal stem cells.
  • Co-culture of step (1) of the present invention can be made using a transwell.
  • one embodiment of the present invention provides a method of inoculating a patient-derived cell on top of a chamber of a transwell and inoculating candidate stem cells on a bottom of a transwell chamber.
  • the candidate stem cells can secrete a variety of substances that can affect the patient-derived cells, thereby increasing the growth of the cells derived from the patient May be promoted, expression of pathological markers may be reduced, or cell differentiation may be promoted.
  • culture in the present invention means to grow the cells under environmental conditions that are appropriately artificially controlled, preferably culture may be carried out in the transwell.
  • the patient derived cells and candidate stem cells can be grown in a conventional medium.
  • the medium may contain a nutritional substance required by the cells to be cultured, that is, the cells to be cultured in order to culture specific cells, and may be mixed with an additional material for a special purpose.
  • the medium may also be referred to as an incubator or a culture medium, and is a concept that includes all natural, synthetic, or selective media.
  • the patient-derived cells and candidate stem cells can be cultured according to conventional culture methods.
  • the co-culture of step (1) may be performed for about 5 to 14 days, preferably 5 to 10 days, more preferably 5 to 7 days. At this time, it is preferable to replace the culture medium every two to three days.
  • Step (2) of the present invention is a step of selecting mesenchymal stem cells by measuring the change in proliferative capacity, differentiation capacity or pathological markers of patient-derived cells.
  • stem cells capable of significantly inducing a desired change than other candidate stem cells by measuring a change in proliferative capacity, differentiation capacity or pathological markers of a patient-derived cell are stemmed according to a patient or disease subtype.
  • Selection as a cell therapeutic agent, and the desired change may include without limitation changes that promote cell proliferation, promote differentiation, or inhibit the expression of pathological markers.
  • the proliferative capacity of step (2) can be confirmed by measuring the survival rate of the cells derived from the patients with degenerative brain disease, and the differentiation capacity is MAP2 (microtubule associated protein 2), NF-200 ( neurofilament 200), Tuj1 (Neuron-specific class III beta-tubulin) and VGLUT2 (vesicular glutamate transporter 2) can be characterized by measuring the expression of one or more neuronal differentiation markers selected from the group consisting of.
  • MAP2 microtubule associated protein 2
  • NF-200 neurofilament 200
  • Tuj1 Neuron-specific class III beta-tubulin
  • VGLUT2 vesicular glutamate transporter 2
  • the change in the pathological marker of step (2) may be characterized by measuring the expression of one or more pathological markers selected from the group consisting of ubiquitin conjugates, amyloid beta and tau proteins, inflammation-related cytokines and the like.
  • the present invention may further comprise the step of analyzing the secreted proteins of the selected stem cells of the step (2), after the selection step of (2).
  • the secreted proteins of the stem cells can be classified by function to select specifically expressed secreted proteins. For example, if stem cells are selected that significantly promote the proliferation of patient-derived cells when co-cultured with patient-derived cells among candidate stem cells, the proteins secreted from the selected stem cells are concentrated and analyzed to significantly promote proliferation of certain proteins. You can see if you can.
  • a screening model was constructed to compare the therapeutic potential of various mesenchymal stem cells (MSCs) against Alzheimer's disease (AD). Specifically, as shown in Figure 1, HT22, a hippocampal neuronal cell line of the mouse was inoculated in a medium essential medium-alpha (MEM-alpha) medium in the bottom of the transwell. Thereafter, amyloid beta 42, an Alzheimer's type dementia-specific biomarker and a toxic molecule, was added to oligomer form in the lower well of the transwell inoculated with the HT22 cells to induce cell death. Alzheimer's dementia model was constructed.
  • MCM-alpha medium essential medium-alpha
  • coculture was performed by inoculating cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (WJ-MSC), or adipose-derived mesenchymal stem cells (Adipose-MSC), respectively.
  • a group not inoculated with MSC was set as a control group, and the effect of preventing cell death by MSCs derived from the above-mentioned different species was confirmed.
  • the expression level of the differentiation marker MAP2 was confirmed through fluorescence.
  • MAP2 protein is a protein that extends to the nerve cell ends during neuronal differentiation, and may be an indicator of whether the cell ends are damaged by neuronal cell death. Therefore, the fluorescence measurement of MAP2 can confirm whether the cells are killed through co-culture of MSC, the results are shown in FIG.
  • the group inoculated and co-cultured with cord blood-derived mesenchymal stem cells (UCB-MSC), umbilical cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC), respectively.
  • UB-MSC cord blood-derived mesenchymal stem cells
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • cord blood-derived mesenchymal stem cells UMB-MSC
  • umbilical cord-derived mesenchymal stem cells WJ-MSC
  • the culture medium at the bottom of the transwell of the adipose-derived mesenchymal stem cell (Adipose-MSC) treated group was collected, and the collected culture solution was concentrated to increase the concentration of the secreted protein.
  • antibody arrays were performed for the culture medium of each of the concentrated groups. Thereafter, the array results were identified using an analysis program to identify proteins showing more than twofold fold changes in each source.
  • neuronal proteins were separately classified among secretory proteins of umbilical cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC) treated groups. Thereafter, the neuronal proteins were reclassified by function to confirm the characteristics of the neuronal proteins secreted by the treatment groups. The results are shown in FIGS. 3 and 4.
  • the umbilical cord-derived mesenchymal stem cells (WJ-MSC) treated group and adipose derived mesenchymal stem cells (Adipose-MSC) treated group showed different protein secretion characteristics.
  • WJ-MSCs umbilical cord-derived mesenchymal stem cells secrete more secretory proteins such as nervous system development, neuronal production, and axon guidance, and secrete more secretory proteins related to the survival of neurons. It was.
  • Adipose-derived mesenchymal stem cells (Adipose-MSC) treated group secreted more proteins involved in the development of the nervous system, signaling pathways, neuronal cell production, cell survival and proliferation It was confirmed that a lot of related proteins secreted.
  • mesenchymal stem cells may be secreted from different populations of secreted proteins for the treatment of diseases, and thus, specific mesenchymal stem cells can be screened for screening patient-specific therapeutic agents.
  • specific mesenchymal stem cells can be screened for screening patient-specific therapeutic agents.
  • co-cultivation of MSCs of different origin and patient-derived disease cells can reduce disease markers or prevent neuronal cell death.
  • MSCs can be screened.
  • the proteins secreted by different MSCs can be identified to select proteins that have an effect on Alzheimer's dementia.
  • Example 1 Based on the screening model of Example 1, in order to build a subtype-specific screening model of the Korean type Alzheimer's dementia, the mesenchymal stem cells of the patient-derived neuronal progenitor cells (NPC) of the Korean type Alzheimer's type dementia The therapeutic ability was confirmed.
  • NPC patient-derived neuronal progenitor cells
  • NPCs AD-NPC
  • MSCs derived from Alzheimer's patient were co-cultured and MSCs having a therapeutic effect were selected.
  • the bottom of the trans well was first coated with poly-L-ornithine (PLO) and laminin.
  • PLO poly-L-ornithine
  • neuroprogenitor APP-NPC or PS-1-NPC of a patient corresponding to the Korean type Alzheimer's dementia subtype APP or PS-1 was inoculated at the bottom of the transwell at 2.5 ⁇ 10 4 / cm 2 .
  • the neural progenitor cells are patient specific cells prepared by collecting somatic cells from dementia patients who visited Samsung Medical Center and dedifferentiating them.
  • WJ-MSC Umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • the stem cell capacity, differentiation capacity and pathological markers of the umbilical cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC) were identified.
  • Stem cell capacity and differentiation capacity were confirmed by Western blot and immunocytochemistry for the expression level of SOX2 / Nestin marker and MAP2 / Tuj1 in AD-NPC co-cultured for 1 week. The results are shown in FIGS. 6 and 7.
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • sAD sporadic AD
  • PS-1-NPC umbilical cord-derived mesenchymal stem cells
  • WJ umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • CCK-8 cell viability assay was performed for 48 hours to confirm the effect of promoting patient-derived NPC proliferation by umbilical cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC).
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • NPCs were different depending on the type of inoculated MSCs. Both sAD-NPC or PS-1-NPC increased proliferation by cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC), but umbilical cord-derived mesenchymal stem cells (WJ-MSC) ) Showed more excellent cell proliferation promoting ability. Therefore, when the purpose of the proliferation of neurons, it can be interpreted that it is preferable to select and use umbilical cord-derived mesenchymal stem cells rather than fat-derived mesenchymal stem cells.
  • WJ-MSC cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • the proliferation of NPCs was different depending on the type of inoculated MSCs.
  • PS-1-NPC significantly increased proliferation by umbilical cord-derived mesenchymal stem cells (WJ-MSC) and adipose-derived mesenchymal stem cells (Adipose-MSC).
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • BruU experiments use the principle of intercalation between DNA when cells divide and proliferate, thus eliminating the interference of metabolism of the cell itself in addition to proliferation, thus enabling more accurate screening of the cell. Therefore, in the case of the purpose of the proliferation of neurons, it can be interpreted that it is preferable to select the umbilical cord-derived mesenchymal stem cells rather than the adipose-derived mesenchymal stem cells, as well as appropriate stem cell therapy according to the disease subtype of each patient. It can be seen that there is a combination, which can be quickly confirmed by the screening method of the present invention.
  • ubiquitin conjugates In order to screen mesenchymal stem cells that have a pathological effect on neuroprogenitor cells, the effects of ubiquitin conjugates on the increase and decrease were identified.
  • neuroprogenitor cells ubiquitin conjugates increase when abnormal intracellular substances accumulate, and ubiquitin increases when diseases such as Alzheimer's occur. Therefore, co-culture of Alzheimer's patient-derived NPCs with adipose-derived mesenchymal stem cells or umbilical cord-derived mesenchymal stem cells was performed by the method according to Example 2, and the increase and decrease of the ubiquitin conjugate was confirmed in the patient-derived NPCs. The increase and decrease of the ubiquitin conjugate was confirmed by Western blot, and the results are shown in FIG. 10.
  • the ubiquitin conjugates increased in sAD, it was confirmed that the level of ubiquitin conjugates is reduced by co-culture with umbilical cord mesenchymal stem cells.
  • the effect of reducing the ubiquitin conjugates was not found in the adipose derived mesenchymal stem cells, but rather showed an increasing aspect, confirming that it is not suitable for reducing the ubiquitin conjugates. Therefore, the mesenchymal stem cells suitable for improving the pathological condition of Alzheimer's through the screening method of the present invention can be identified and selected from the umbilical cord-derived mesenchymal stem cells.
  • NPCs were differentiated to obtain degenerative subtypes of neurons and screening using the same.
  • the dementia subtype was a mutation of the genetic subtype APP (Amyloid Precursor Protein) / mutation of PS1 (Presenilin 1) / non-genetic subtype sAD (sporadic AD), and after the production of patient-derived dedifferentiated stem cells (iPSC), Cells differentiated by neural lineage were obtained and used for the experiment.
  • APP Amyloid Precursor Protein
  • PS1 Presenilin 1
  • iPSC patient-derived dedifferentiated stem cells
  • the screening method is similar to that of Example 2, but in order to co-culture MSC and neurons, inoculated NPCs of Korean Alzheimer's dementia subtypes at a rate of 2x10 4 / cm 2 and differentiated for 10 weeks to differentiate neurons by dementia subtypes.
  • Cells were obtained.
  • the obtained dementia subtype neurons were inoculated at the bottom of the transwell at 2.5x10 4 / cm 2 , and umbilical cord-derived mesenchymal stem cells (WJ-MSC) or adipose-derived mesenchymal stem cells (Adipose-MSC) were inserted into the insert chamber. Each was inoculated to be 4 / cm 2 .
  • WJ-MSC umbilical cord-derived mesenchymal stem cells
  • Adipose-MSC adipose-derived mesenchymal stem cells
  • Co-cultivation was carried out through the method of 4.1, and mesenchymal stem cells were effectively screened and selected to effectively reduce the pathological characteristics of Alzheimer's disease through the method of 3.3.
  • an experimental group (B + G + N) containing only BDNF, GDNF, and NT3, which are reagents used for differentiating neurons from neuronal progenitor cells, was used. It is shown in 12.
  • the ubiquitin conjugate was increased in the dementia patient-derived neurons, and the level of the ubiquitin conjugate was decreased by co-culture with adipose-derived mesenchymal stem cells or umbilical cord-derived mesenchymal stem cells.
  • the ubiquitin conjugate reduction effect was more excellent in umbilical cord-derived mesenchymal stem cells than adipose derived mesenchymal stem cells. Therefore, the mesenchymal stem cells suitable for improving the pathological condition of Alzheimer's through the screening method of the present invention can be identified and selected from the umbilical cord-derived mesenchymal stem cells.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La présente invention concerne un procédé de recherche par criblage d'un agent thérapeutique spécifique d'un patient. Lors de l'utilisation du procédé de recherche par criblage d'un agent thérapeutique spécifique d'un patient de la présente invention, il est possible d'identifier et de sélectionner la capacité thérapeutique de cellules souches mésenchymateuses de diverses origines par rapport à des sous-types de maladie ou à des effecteurs de maladie. De plus, il est possible de confirmer les caractéristiques de la protéine sécrétée qui agit avec une efficacité élevée ou une faible efficacité, par l'analyse des protéines sécrétées par les cellules souches mésenchymateuses sélectionnées, et par conséquent, l'avantage est qu'un agent thérapeutique personnalisé adapté à la nature spécifique de la maladie de chaque patient peut être proposé.
PCT/KR2017/009839 2016-09-23 2017-09-07 Procédé de recherche par criblage d'un agent thérapeutique à base de cellules souches spécifiques d'un patient Ceased WO2018056616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160122492 2016-09-23
KR10-2016-0122492 2016-09-23

Publications (1)

Publication Number Publication Date
WO2018056616A1 true WO2018056616A1 (fr) 2018-03-29

Family

ID=61690911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/009839 Ceased WO2018056616A1 (fr) 2016-09-23 2017-09-07 Procédé de recherche par criblage d'un agent thérapeutique à base de cellules souches spécifiques d'un patient

Country Status (2)

Country Link
KR (1) KR20180033062A (fr)
WO (1) WO2018056616A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102203861B1 (ko) * 2019-05-10 2021-01-15 주식회사 아이피에스바이오 아밀로이드 전구체 단백질 돌연변이(v715m)를 갖는 알츠하이머병 환자의 유도만능 줄기세포
KR102816716B1 (ko) * 2021-11-02 2025-06-04 가톨릭대학교 산학협력단 파브리병 치료제 개발을 위한 파브리병 환자 맞춤형 오가노이드를 활용한 질환 모델링

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090008155A (ko) * 2007-07-16 2009-01-21 가톨릭대학교 산학협력단 중간엽기질세포를 이용한 성체줄기세포의 자가재생산을촉진하는 방법
KR20090055691A (ko) * 2007-11-29 2009-06-03 메디포스트(주) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
US20110262956A1 (en) * 2008-10-07 2011-10-27 Guillermo Munoz Elias Co-culture compositions and methods
WO2014148646A1 (fr) * 2013-03-21 2014-09-25 国立大学法人京都大学 Cellule souche pluripotente pour l'induction de la différenciation neuronale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090008155A (ko) * 2007-07-16 2009-01-21 가톨릭대학교 산학협력단 중간엽기질세포를 이용한 성체줄기세포의 자가재생산을촉진하는 방법
KR20090055691A (ko) * 2007-11-29 2009-06-03 메디포스트(주) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
US20110262956A1 (en) * 2008-10-07 2011-10-27 Guillermo Munoz Elias Co-culture compositions and methods
WO2014148646A1 (fr) * 2013-03-21 2014-09-25 国立大学法人京都大学 Cellule souche pluripotente pour l'induction de la différenciation neuronale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOU, LINGLING: "Induction of umbilical cord blood mesenchymal stem cells into neuron-like cells in vitro", INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, pages 256 - 261, XP036521474, DOI: doi:10.1007/BF02983804 *

Also Published As

Publication number Publication date
KR20180033062A (ko) 2018-04-02

Similar Documents

Publication Publication Date Title
Barak et al. Human iPSC-derived neural models for studying Alzheimer’s disease: from neural stem cells to cerebral organoids
Guo et al. Cotransplant of neural stem cells and NT-3 gene modified Schwann cells promote the recovery of transected spinal cord injury
Kang et al. Characteristic analyses of a neural differentiation model from iPSC-derived neuron according to morphology, physiology, and global gene expression pattern
Okano Stem cell biology of the central nervous system
Li et al. Isolation and characterization of neural crest progenitors from adult dorsal root ganglia
Jadhav et al. Development and neurogenic potential of Müller glial cells in the vertebrate retina
Kurtenbach et al. Cell-based therapy restores olfactory function in an inducible model of hyposmia
Dezonne et al. Derivation of functional human astrocytes from cerebral organoids
Rao Multipotent and restricted precursors in the central nervous system
Shim et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression
Li et al. Multipotent stem cells isolated from the adult mouse retina are capable of producing functional photoreceptor cells
Shihabuddin et al. The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease
Chen et al. Transplanted bone marrow stromal cells migrate, differentiate and improve motor function in rats with experimentally induced cerebral stroke
Liu et al. The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain
Angelastro et al. Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes
Xu et al. Cortical interneuron fate determination: diverse sources for distinct subtypes?
JP6761409B2 (ja) 多能性幹細胞由来細胞から形成された神経回路網
Smith et al. Porcine neural progenitors require commitment to the oligodendrocyte lineage prior to transplantation in order to achieve significant remyelination of demyelinated lesions in the adult CNS
Jiao et al. Cell-cell connection enhances proliferation and neuronal differentiation of rat embryonic neural stem/progenitor cells
Faijerson et al. Reactive astrogliosis induces astrocytic differentiation of adult neural stem/progenitor cells in vitro
Poltavtseva et al. Evaluation of progenitor cell cultures from human embryos for neurotransplantation
Goldman et al. Neural progenitor cells of the adult brain
Ortega et al. Live imaging of adult neural stem cells in rodents
Shah et al. A chromatin modulator sustains self-renewal and enables differentiation of postnatal neural stem and progenitor cells
Zhu et al. Efficient generation of corticofugal projection neurons from human embryonic stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17853330

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17853330

Country of ref document: EP

Kind code of ref document: A1